Results 161 to 170 of about 325,649 (265)

The Emerging Biomarkers in Chronic Obstructive Pulmonary Disease: A Narrative Review. [PDF]

Diagnostics (Basel)
Phillips KM, Lavere PF, Hanania NA, Adrish M.   +3 more
europepmc   +1 more source

Urban Living, Tobacco Smoking, and Chronic Obstructive Pulmonary Disease: A Study in Athens

, 1992
Αναστασία Τζώνου, George Maragoudakis, Dimitrios Trichopoulos, X Zavitsanos, Ioanna Dimopoulou, Nektaria Toupadaki, Jenny Kremastinou   +6 more
openalex   +1 more source

Out-patient rehabilitation improves activities of daily living, quality of life and exercise tolerance in chronic obstructive pulmonary disease [PDF]

, 1997
KE Bendstrup, J. Ingemann Jensen, S. Holm, Boel Bengtsson   +3 more
openalex   +1 more source

Elexacaftor–Tezacaftor–Ivacaftor Improves Sinonasal Outcomes in Young Children With Cystic Fibrosis

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Severe chronic rhinosinusitis (CRS) is a near universal manifestation of cystic fibrosis. Elexacaftor/tezacaftor/ivacaftor (ETI) is an oral, small molecule, highly effective Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) corrector–potentiator drug.
Amanda L. Stapleton, Adam Kimple, Jennifer L. Goralski, Daniel M. Beswick, Anshika Gupta, Douglas A. Li, Barton F. Branstetter, S. Mehdi Nouraie, Amber D. Shaffer, Brent Senior, Anna C. Zemke   +10 more
wiley   +1 more source

A comment on "Association between oral microbiome diversity and chronic obstructive pulmonary disease in the US population". [PDF]

J Transl Med
Luo M, Xin K, Luo T.
europepmc   +1 more source

Beyond the Lung. Impact of Elexacaftor/Tezacaftor/Ivacaftor on Sinonasal Disease in Children With Cystic Fibrosis

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Elexacaftor/tezacaftor/ivacaftor (ETI) is a Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) therapy that improves pulmonary function and chronic rhinosinusitis (CRS) in cystic fibrosis (CF) adults with at least one copy of the F508del CFTR mutation.
Margaux Petitjean, Alexia Letierce, Anne‐Sophie Bonnel, Philippe Reix, Eric Deneuville, Nathalie Stremler, Romain Luscan, Vincent Couloigner, Laurent Mely, Katia Bessaci, Guillaume Labbe, Christophe Marguet, Mairead Kelly‐Aubert, Fatiha Hassani, Isabelle Sermet‐Gaudelus, François Simon, the MODUL‐CF Study Group   +16 more
wiley   +1 more source

Paradigm Shift in the Treatment of Chronic Obstructive Pulmonary Disease Improves Patient Outcomes. [PDF]

Int J Chron Obstruct Pulmon Dis
Huang YJ, Wang KY, Chien WC, Chung CH, Kao LT, Kao S, Chian CF.   +6 more
europepmc   +1 more source

Improvement in Mood, Physical Symptoms, and Function With Nortriptyline for Depression in Patients With Chronic Obstructive Pulmonary Disease

, 1992
Soo Borson, Gwendolyn J. McDonald, Terence C. Gayle, Mark Deffebach, S. Lakshminarayan, Craig VanTuinen   +5 more
openalex   +1 more source

Mechanical ventilation of the patient with severe chronic obstructive pulmonary disease [PDF]

, 1998
Mark T. Gladwin, D J Pierson
openalex   +1 more source

Superior Benefits of Combining Mepolizumab With Sinus Surgery Compared to Mepolizumab Alone: Results From a Randomised 6‐Month Trial

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Chronic rhinosinusitis with nasal polyps (CRSwNP) significantly impacts patients’ quality of life (QoL). Standard treatments include nasal irrigations, nasal steroids, systemic corticosteroids, and functional endoscopic sinus surgery (FESS).
Anne‐Sophie Homøe, Kasper Aanæs, Jens Even Tidemandsen, Haase Christiane Holbaek, Rubek Niclas, Samuelsen Grethe Badsberg, Larsen Bent Ivan Holmegaard, Vibeke Backer   +7 more
wiley   +1 more source